Ranked by reported Q2 2025 13F market value
Share of total reported institutional value in ENTO held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 37K | $15K | 0.0% | 0.767% | 0.00% |
| 2 | UBS Group AG | 21K | $8K | -64.5% | 0.431% | 0.00% |
| 3 | TWO SIGMA SECURITIES, LLC | 16K | $6K | β | 0.331% | 0.00% |
| 4 | JANE STREET GROUP, LLC | 13K | $5K | β | 0.267% | 0.00% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 13K | $5K | β | 0.262% | 0.00% |
| 6 | CITADEL ADVISORS LLC | 12K | $5K | β | 0.261% | 0.00% |
| 7 | Tower Research Capital LLC (TRC) | 5K | $2K | -0.1% | 0.106% | 0.00% |
| 8 | SBI Securities Co., Ltd. | 3K | $1K | 0.0% | 0.069% | 0.00% |
| 9 | BANK OF AMERICA CORP /DE/ | 42 | $17 | +5.0% | 0.001% | 0.00% |
| 10 | US BANCORP \DE\ | 1 | $0 | 0.0% | 0.000% | 0.00% |
| 11 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | β | 0.000% | β |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in ENTO β a direct measure of their conviction.
Filings activity in ENTO during Q2 2025, grouped by how each filer changed its position.
Institutions that opened a new ENTO position in Q2 2025
Institutions that fully closed their ENTO position in Q2 2025
6 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2025 | 11 | +22% | 0.35% | 0.05 pp | $0M | 12% |
| Q1 2025 | 9 | 10% | 0.40% | +0.07 pp | $0M | +21% |
| Q4 2024 | 10 | 9.1% | 0.33% | +0.17 pp | $0M | +113% |
| Q3 2024 | 11 | +22% | 0.16% | 1.18 pp | $0M | 88% |
| Q2 2024 | 9 | +29% | 1.34% | +0.04 pp | $0M | +3.2% |
| Q1 2024 | 7 | β | 1.30% | β | $0M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying ENTO stock.
Based on Q2 2025 13F filings, institutional ownership of Entero Therapeutics, Inc. stands at 0.4%, held across 11 reporting institutions.
GEODE CAPITAL MANAGEMENT, LLC is the largest reported institutional holder of ENTO, with approximately 36,560 shares worth $0.00B as of Q2 2025.
Yes β 4 widely-followed marquee investors appear among the top 25 institutional holders of ENTO, including TWO SIGMA SECURITIES, LLC, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for ENTO is 66 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
4 institutions opened new positions in ENTO during Q2 2025, while 2 fully exited. 0 added to existing positions and 5 trimmed.
ENTO institutional ownership fell by 0.05 percentage points quarter-over-quarter, with a net change of +2 holders.
The top 10 institutions account for 100.0% of all reported 13F value in ENTO, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Entero Therapeutics, Inc. (ENTO) Institutional Ownership